Weekly Promotions

The Digestive Health - Advanced contains the following tests

• C-Reactive Protein (CRP) 
• CBC (includes Differential and Platelets) 
• Comprehensive Metabolic Panel (CMP)
• Fecal Globin by Immunochemistry (InSure®) 
• Ferritin
• Folate, Serum
• Iron and Total Iron Binding Capacity (TIBC)
• QuestAssureD™ 25-Hydroxyvitamin D (D2, D3), LC/MS/MS 
• Sed Rate by Modified Westergren (ESR)
• Transferrin
• Vitamin B12 (Cobalamin) 
• Celiac Disease Comprehensive Panel (w/ Reflexes)

Specimens from children less than 4 years of age (i.e., less than 48 months) are not appropriate for this test. The test for children 4 years of age and younger is the Celiac Disease Comprehensive Panel, Infant (test code 15981).

Includes

Tissue Transglutaminase, IgA with Reflexes; Total IgA with Reflex

IMPORTANT - Note this is Reflex Test which if additional tests are run you will be charged for the specific tests that the lab peforms. Additional test will be run if the following criteria are met.

If the Tissue Transglutaminase IgA is positive, 

1. Endomysial Antibody Screen (IgA) will be performed at an additional charge (CPT code(s): 86255).

If the Endomysial Antibody Screen (IgA) is positive, 

2. Endomysial Antibody Titer will be performed at an additional charge (CPT code(s): 86256).

If the Total IgA is less than the lower limit of the reference range, based on age, 

3. Tissue Transglutaminase IgG will be performed at an additional charge (CPT code(s): 83516).

Clinical Significance

Celiac disease is caused by an immune response to gluten in genetically sensitive individuals. The diagnosis is largely based on a biopsy of the small intestine, but serologic tests also help support a diagnosis and may assist identification of patients who may require biopsy.

Tissue transglutaminase antibodies (tTG, IgA) is a marker with 95% sensitivity and specificity. Total IgA is measured because 2-3% of celiac disease patients are IgA deficient. Because tTG, IgA, and anti-Gliadin IgA tend to decrease in patients on a gluten-free diet, these markers are also used to assess dietary compliance.

The endomysial antibody (EMA, IgA) assay has high specificity for celiac disease and is used to confirm positive anti-tTG results.

Digestive Health - Basic contains the following tests

• CBC (includes Differential and Platelets) 
• Comprehensive Metabolic Panel (CMP)
• Fecal Globin by Immunochemistry (InSure®) 
• Celiac Disease Comprehensive Panel (w/ Reflexes)

Specimens from children less than 4 years of age (i.e., less than 48 months) are not appropriate for this test. The test for children 4 years of age and younger is the Celiac Disease Comprehensive Panel, Infant (test code 15981).

Includes

Tissue Transglutaminase, IgA with Reflexes; Total IgA with Reflex

IMPORTANT - Note this is Reflex Test which if additional tests are run you will be charged for the specific tests that the lab peforms. Additional test will be run if the following criteria are met.

If the Tissue Transglutaminase IgA is positive, 

1. Endomysial Antibody Screen (IgA) will be performed at an additional charge (CPT code(s): 86255).

If the Endomysial Antibody Screen (IgA) is positive, 

2. Endomysial Antibody Titer will be performed at an additional charge (CPT code(s): 86256).

If the Total IgA is less than the lower limit of the reference range, based on age, 

3. Tissue Transglutaminase IgG will be performed at an additional charge (CPT code(s): 83516).

Clinical Significance

Celiac disease is caused by an immune response to gluten in genetically sensitive individuals. The diagnosis is largely based on a biopsy of the small intestine, but serologic tests also help support a diagnosis and may assist identification of patients who may require biopsy.

Tissue transglutaminase antibodies (tTG, IgA) is a marker with 95% sensitivity and specificity. Total IgA is measured because 2-3% of celiac disease patients are IgA deficient. Because tTG, IgA, and anti-Gliadin IgA tend to decrease in patients on a gluten-free diet, these markers are also used to assess dietary compliance.

The endomysial antibody (EMA, IgA) assay has high specificity for celiac disease and is used to confirm positive anti-tTG results.

Digestive Health - Basic Plus contains the followwing tests: 

• C-Reactive Protein (CRP) 
• CBC (includes Differential and Platelets) 
• Comprehensive Metabolic Panel (CMP)
• Fecal Globin by Immunochemistry (InSure®) 
• Ferritin
• Iron and Total Iron Binding Capacity (TIBC)
• Sed Rate by Modified Westergren (ESR)
• Celiac Disease Comprehensive Panel (w/ Reflexes)

 Specimens from children less than 4 years of age (i.e., less than 48 months) are not appropriate for this test. The test for children 4 years of age and younger is the Celiac Disease Comprehensive Panel, Infant (test code 15981).

Includes

Tissue Transglutaminase, IgA with Reflexes; Total IgA with Reflex

IMPORTANT - Note this is Reflex Test which if additional tests are run you will be charged for the specific tests that the lab peforms. Additional test will be run if the following criteria are met.

If the Tissue Transglutaminase IgA is positive, 

1. Endomysial Antibody Screen (IgA) will be performed at an additional charge (CPT code(s): 86255).

If the Endomysial Antibody Screen (IgA) is positive, 

2. Endomysial Antibody Titer will be performed at an additional charge (CPT code(s): 86256).

If the Total IgA is less than the lower limit of the reference range, based on age, 

3. Tissue Transglutaminase IgG will be performed at an additional charge (CPT code(s): 83516).

Clinical Significance

Celiac disease is caused by an immune response to gluten in genetically sensitive individuals. The diagnosis is largely based on a biopsy of the small intestine, but serologic tests also help support a diagnosis and may assist identification of patients who may require biopsy.

Tissue transglutaminase antibodies (tTG, IgA) is a marker with 95% sensitivity and specificity. Total IgA is measured because 2-3% of celiac disease patients are IgA deficient. Because tTG, IgA, and anti-Gliadin IgA tend to decrease in patients on a gluten-free diet, these markers are also used to assess dietary compliance.

The endomysial antibody (EMA, IgA) assay has high specificity for celiac disease and is used to confirm positive anti-tTG results.

Digestive Health - Comprehensive contains the following tests: 

• C-Reactive Protein (CRP) 
• CBC (includes Differential and Platelets) 
• Comprehensive Metabolic Panel (CMP)
• Fecal Globin by Immunochemistry (InSure®) 
• Ferritin
• Folate, Serum
• Gliadin (Deamidated Peptide) Antibody (IgA) 
• Gliadin (Deamidated Peptide) Antibody (IgG) 
• Iron and Total Iron Binding Capacity (TIBC)
• Lipid Panel with Ratios
• Magnesium
• Prealbumin 
• QuestAssureD™ 25-Hydroxyvitamin D (D2, D3), LC/MS/MS 
• Sed Rate by Modified Westergren (ESR)
• Transferrin
• TSH
• Vitamin A (Retinol)
• Vitamin B12 (Cobalamin) 
• Vitamin K
• Celiac Disease Comprehensive Panel (w/ Reflexes)

Specimens from children less than 4 years of age (i.e., less than 48 months) are not appropriate for this test. The test for children 4 years of age and younger is the Celiac Disease Comprehensive Panel, Infant (test code 15981).

Includes

Tissue Transglutaminase, IgA with Reflexes; Total IgA with Reflex

IMPORTANT - Note this is Reflex Test which if additional tests are run you will be charged for the specific tests that the lab peforms. Additional test will be run if the following criteria are met.

If the Tissue Transglutaminase IgA is positive, 

1. Endomysial Antibody Screen (IgA) will be performed at an additional charge (CPT code(s): 86255).

If the Endomysial Antibody Screen (IgA) is positive, 

2. Endomysial Antibody Titer will be performed at an additional charge (CPT code(s): 86256).

If the Total IgA is less than the lower limit of the reference range, based on age, 

3. Tissue Transglutaminase IgG will be performed at an additional charge (CPT code(s): 83516).

Clinical Significance

Celiac disease is caused by an immune response to gluten in genetically sensitive individuals. The diagnosis is largely based on a biopsy of the small intestine, but serologic tests also help support a diagnosis and may assist identification of patients who may require biopsy.

Tissue transglutaminase antibodies (tTG, IgA) is a marker with 95% sensitivity and specificity. Total IgA is measured because 2-3% of celiac disease patients are IgA deficient. Because tTG, IgA, and anti-Gliadin IgA tend to decrease in patients on a gluten-free diet, these markers are also used to assess dietary compliance.

The endomysial antibody (EMA, IgA) assay has high specificity for celiac disease and is used to confirm positive anti-tTG results.

IMPORTANT - Note the Estradiol test included in this panel is not for children that have yet to start their menstrual cycle.  If this test is ordered for a child that has yet to begin their menstrual cycle Quest Diagnostics labs will substitute Estradiol, Free, LC/MS/MS at an additional fee of $290.00

IMPORTANT - Note the Estradiol test included in this panel is not for children that have yet to start their menstrual cycle.  If this test is ordered for a child that has yet to begin their menstrual cycle Quest Diagnostics labs will substitute Estradiol, Free, LC/MS/MS at an additional fee of $290.00

IMPORTANT - Note the Estradiol test included in this panel is not for children that have yet to start their menstrual cycle.  If this test is ordered for a child that has yet to begin their menstrual cycle Quest Diagnostics labs will substitute Estradiol, Free, LC/MS/MS at an additional fee of $290.00

IMPORTANT - Note the Estradiol test included in this panel is not for children that have yet to start their menstrual cycle.  If this test is ordered for a child that has yet to begin their menstrual cycle Quest Diagnostics labs will substitute Estradiol, Free, LC/MS/MS at an additional fee of $290.00

IMPORTANT - Note the Estradiol test included in this panel is not for children that have yet to start their menstrual cycle.  If this test is ordered for a child that has yet to begin their menstrual cycle Quest Diagnostics labs will substitute Estradiol, Free, LC/MS/MS at an additional fee of $290.00

Measuring Lipid Subclasses using Ion Mobility

The way most doctors test for heart disease is with a lipid panel. It helps detect what HDL (good) and LDL (bad) cholesterol are, so hopefully you can reduce your risk of a possible cardiac event such as a heart attack. Nearly half of all heart attack patients were found to have no prior risk which would indicate they were heading toward an attack.

Quest Diagnostics offers advanced cardiovascular tests that help provide a more accurate and individualized picture of risk. The tests look beyond just HDL and LDL cholesterol to identify undiagnosed (or additional) risk.

These advanced cardiovascular tests, along with your lipid panel, will provide more information that you and your doctor can use to understand your complete cardiovascular health.

Lipid Subclasses as measured by Ion Mobility Technology

Knowing what particles make up your LDL and HDL cholesterol may be important. Ion Mobility Technology provides subclass separation that will allow your healthcare provider to identify your cardiovascular risk over time. Following the change in your lipid profile as you respond to diet, exercise and possible medication to reduce your cardiovascular risk is important. Ion Mobility provides the opportunity to determine if treatment is working and if not, optimize the aggressiveness of therapy to hopefully make a difference that can be seen in the Ion Mobility measurement and graphical representation of your LDL and HDL particles. 

Cardio IQ™ Lipoprotein Fractionation, Ion Mobility 
Cardio IQ™ Lipid Panel
Cardio IQ™ Direct LDL 
Cardio IQ™ Apolipoprotein Evaluation 
Cardio IQ™ Lipoprotein (A)

Apo B

• Apo B is a direct measurement of the number of lipoprotein particles, including LDL (“bad cholesterol”), IDL, and VLDL
• A high Apo B number indicates increased risk for heart disease
• Certain medications, improved eating habits, increased physical activity, and loss of body fat are some ways to
  improve Apo B

Lipoprotein (A) - Lp(a)

• High levels of Lp(a) are associated with increased risk of cardiovascular disease and stroke
• Lp(a) levels may be influenced by genetics. Diet and exercise have limited to no effect on lowering Lp(a); however, certain
  medications can lower levels

Cardio IQ® Apolipoprotein Evaluation - (APOLIPOPROTEIN A1, APOLIPOPROTEIN B and APOLIPOPROTEIN B/A1 RATIO)

• Apolipoprotein A1 is the primary protein associated with HDL cholesterol. Like HDL cholesterol, increased concentrations are associated with reduced risk of cardiovascular disease. Apolipoprotein B-100 is the primary protein associated with LDL cholesterol and other lipid particles. Like LDL cholesterol, increased concentrations are associated with increased risk of cardiovascular disease. The ratio of these two apolipoproteins correlates with risk of cardiovascular disease.

Cardio IQ Advanced Lipid Panel Plus and Inflammation Panel

Measuring Lipid Subclasses using Ion Mobility

The way most doctors test for heart disease is with a lipid panel. It helps detect what HDL (good) and LDL (bad) cholesterol are, so hopefully you can reduce your risk of a possible cardiac event such as a heart attack. Nearly half of all heart attack patients were found to have no prior risk which would indicate they were heading toward an attack.

Quest Diagnostics offers advanced cardiovascular tests that help provide a more accurate and individualized picture of risk. The tests look beyond just HDL and LDL cholesterol to identify undiagnosed (or additional) risk.

These advanced cardiovascular tests, along with your lipid panel, will provide more information that you and your doctor can use to understand your complete cardiovascular health.

Lipid Subclasses as measured by Ion Mobility Technology

Knowing what particles make up your LDL and HDL cholesterol may be important. Ion Mobility Technology provides subclass separation that will allow your healthcare provider to identify your cardiovascular risk over time. Following the change in your lipid profile as you respond to diet, exercise and possible medication to reduce your cardiovascular risk is important. Ion Mobility provides the opportunity to determine if treatment is working and if not, optimize the aggressiveness of therapy to hopefully make a difference that can be seen in the Ion Mobility measurement and graphical representation of your LDL and HDL particles. 

Cardio IQ™ Lipoprotein Fractionation, Ion Mobility 

Cardio IQ™ Lipid Panel

Cardio IQ™ Direct LDL 

Cardio IQ™ Apolipoprotein Evaluation 

Cardio IQ™ Lipoprotein (A)

Apo B

• Apo B is a direct measurement of the number of lipoprotein particles, including LDL (“bad cholesterol”), IDL, and VLDL
• A high Apo B number indicates increased risk for heart disease
• Certain medications, improved eating habits, increased physical activity, and loss of body fat are some ways to
  improve Apo B

Lipoprotein (A) - Lp(a)

• High levels of Lp(a) are associated with increased risk of cardiovascular disease and stroke
• Lp(a) levels may be influenced by genetics. Diet and exercise have limited to no effect on lowering Lp(a); however, certain
  medications can lower levels

Cardio IQ® Apolipoprotein Evaluation - (APOLIPOPROTEIN A1, APOLIPOPROTEIN B and APOLIPOPROTEIN B/A1 RATIO)

• Apolipoprotein A1 is the primary protein associated with HDL cholesterol. Like HDL cholesterol, increased concentrations are associated with reduced risk of cardiovascular disease. Apolipoprotein B-100 is the primary protein associated with LDL cholesterol and other lipid particles. Like LDL cholesterol, increased concentrations are associated with increased risk of cardiovascular disease. The ratio of these two apolipoproteins correlates with risk of cardiovascular disease.

Inflammation Panel

hs-CRP

• High levels of C-Reactive Protein (CRP) indicate inflammation due to infection or tissue injury
• Modestly elevated CRP levels may be associated with increased heart disease risk. If both CRP and Lp-PLA2 levels are
  high, your risk for a heart attack or stroke increases significantly
• Certain medications and food may have anti-inflammatory benefits

Lp-PLA2

• High levels of Lp-PLA2 can predict risk of a heart attack or stroke
• When both Lp-PLA2 levels and systolic blood pressure are high, stroke risk increases significantly
• Certain medications can reduce levels of Lp-PLA2 

Cardio IQ® ASCVD Risk Panel with Score 

This panel provides the 10-year and lifetime risk of atherosclerotic cardiovascular disease (ASCVD) using lipid results with anthropomorphic data and family history. 
The ASCVD risk assessment is recommended in the 2013 ACC/AHA Guidelines on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults.

IMPORTANT: For risk calculations to be performed, the following patient-specific information must be provided and recorded at the time of specimen collection:

• Age: Years 
• Gender: M (for male) or F (for female) 
• Height Feet: Feet 
• Height Inches: Inches 
• Weight: lbs 
• Race-African American: Y (for yes) or N (for no) 
• Systolic Blood Pressure: mmHg
• Diastolic Blood Pressure: mmHg
• Treatment for High B.P.: Y (for yes) or N (for no) 
• Diabetes Status: Y (for yes) or N (for no)
• Parental History of Diab: Y (for yes) or N (for no) 
• Smoking Status: Y (for Yes) or N (for no)

Cardio IQ® Diabetes and ASCVD Risk Panel with Scores - Includes:  Cardio IQ® Glucose; Cardio IQ® Hemoglobin A1c; Cardio IQ® Cholesterol, Total; Cardio IQ® HDL Cholesterol; Cardio IQ® Triglycerides; Cardio IQ® Non-HDL and Calculated Components; Cardio IQ® Risks and Personal Factors

If Triglyceride is >400 mg/dL, Cardio IQ® Direct LDL will be performed at an additional charge (CPT code(s): 83721).

Clinical Significance

The increasing prevalence of obesity has led to an epidemic of diabetes mellitus and related complications, including ASCVD. Prediction of the risk of ASCVD and of developing diabetes in the Cardio IQ® lab report will simplify and improve the communication of those risks to patients.

This panel provides the 10-year and lifetime risk of ASCVD events and the 8-year risk of developing diabetes. The lipid panel results will aid in the assessment of ASCVD. Assessment of 10-year risk of a first atherosclerotic cardiovascular (ASCVD) event is recommended by the 2013 ACC/AHA Guidelines on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults. These guidelines recommend initiating statin therapy based on 10-year ASCVD risk score. Assessment of 8-year risk of developing diabetes mellitus is based on laboratory test results with anthropomorphic data and family history. This algorithm was developed in the Framingham cohort, and is intended to aid in the identification of patients at risk for developing diabetes, permitting pharmacological or lifestyle interventions.

IMPORTANT: For risk calculations to be performed, the following patient-specific information must be provided and recorded at the time of specimen collection:

• Age: Years 
• Gender: M (for male) or F (for female) 
• Height Feet: Feet 
• Height Inches: Inches 
• Weight: lbs 
• Race-African American: Y (for yes) or N (for no) 
• Systolic Blood Pressure: mmHg
• Diastolic Blood Pressure: mmHg
• Treatment for High B.P.: Y (for yes) or N (for no) 
• Diabetes Status: Y (for yes) or N (for no)
• Parental History of Diab: Y (for yes) or N (for no) 
• Smoking Status: Y (for Yes) or N (for no)

Cardio IQ Lp-PLA2 Activity

Clinical Significance

Lipoprotein-associated phospholipase A2 (Lp-PLA2), also known as platelet activating factor Acetylhydrolase, is an inflammatory enzyme that circulates bound mainly to low density lipoproteins and has been found to be localized and enriched in atherosclerotic plaques. In multiple clinical trials, Lp-PLA2 activity has been shown to be an independent predictor of coronary heart disease and stroke in the general population. Measurement of Lp-PLA2 may be used along with traditional cardiovascular risk factor measures for identifying individuals at higher risk of cardiovascular disease events. Clinical management may include beginning or intensifying risk reduction strategies. The activity assay is an enzyme assay run on an automated chemistry platform.

Keto Lab Test Panel - Advanced includes the following tests.

• C-Peptide
• CBC (includes Differential and Platelets)
• Comprehensive Metabolic Panel (CMP)
• Ferritin
• Hemoglobin A1c (HgbA1C)
• hs-CRP
• Insulin
• Lipid Panel, Cardio IQ™
• Lipoprotein (a), Cardio IQ™
• Lipoprotein Fractionation, Ion Mobility, Cardio IQ™
• QuestAssureD™ 25-Hydroxyvitamin D (D2, D3), LC/MS/MS
• T3, Free
• T4 (Thyroxine), Total
• TSH
• Uric Acid
• Urinalysis (UA), Complete

Keto Lab Test Panel - Basic includes the following tests.

• CBC (includes Differential and Platelets)
• Comprehensive Metabolic Panel (CMP)
• Hemoglobin A1c (HgbA1C)
• Insulin
• Lipid Panel, Cardio IQ™
• Lipoprotein Fractionation, Ion Mobility, Cardio IQ™
• TSH
• Uric Acid
• Urinalysis (UA), Complete

Keto Lab Test Panel - Basic Plus includes the following tests.

• CBC (includes Differential and Platelets)
• Comprehensive Metabolic Panel (CMP)
• Ferritin
• Hemoglobin A1c (HgbA1C)
• Insulin
• Lipid Panel, Cardio IQ™
• Lipoprotein (a), Cardio IQ™
• Lipoprotein Fractionation, Ion Mobility, Cardio IQ™
• QuestAssureD™ 25-Hydroxyvitamin D (D2, D3), LC/MS/MS
• T3, Free
• T4 (Thyroxine), Total
• TSH
• Uric Acid
• Urinalysis (UA), Complete

Keto Lab Test Panel - Comprehensive includes the following tests.

• Apolipoprotein B, Cardio IQ™ 
• C-Peptide
• CBC (includes Differential and Platelets) 
• Comprehensive Metabolic Panel (CMP)
• Ferritin
• Hemoglobin A1c (HgbA1C)
• hs-CRP
• Insulin
• Lipid Panel, Cardio IQ™ 
• Lipoprotein (a), Cardio IQ™ 
• Lipoprotein Fractionation, Ion Mobility, Cardio IQ™ 
• Magnesium
• QuestAssureD™ 25-Hydroxyvitamin D (D2, D3), LC/MS/MS 
• T3, Free
• T4 (Thyroxine), Total
• TSH
• Uric Acid
• Urinalysis (UA), Complete
• Vitamin B12 (Cobalamin)

ABO Group and Rh Type

Blood typing is used to determine an individual's blood group, to establish whether a person is blood group A, B, AB, or O and whether he or she is Rh positive or Rh negative.

The Different Blood Types

There are four major blood groups and eight different blood types. Doctors call this the ABO Blood Group System.

The groups are based on whether or not you have two specific antigens -- A and B:

• Group A has the A antigen and B antibody.
• Group B has the B antigen and the A antibody.
• Group AB has A and B antigens but neither A nor B antibodies.
• Group O doesn’t have A or B antigens but has both A and B antibodies.

There’s also a third kind of antigen called the Rh factor. You either have this antigen (meaning your blood type is “Rh+” or “positive”), or you don’t (meaning your blood type is “Rh-” or “negative”). So, from the four blood groups, there are eight blood types:

• A positive or A negative
• B positive or B negative
• AB positive or AB negative
• O positive or O negative

Useful in the diagnosis of hypochromic, microcytic anemias. Decreased in iron deficiency anemia and increased in iron overload.

Lactate Dehydrogenase (LD) (LDH)

Elevations in serum lactate dehydrogenase occur from myocardial infarction, liver disease, pernicious and megaloblastic anemia, pulmonary emboli, malignancies, and muscular dystrophy

Measles Antibody IgG - to establish whether you have immunity to measles due to a previous infection or to vaccination.

Measles, also known as rubeola, causes fever, irritability, respiratory illness, and the characteristic skin rash. Immunization has greatly diminished the incidence of measles. The presence of IgG is consistent with immunity or prior exposure. 

Alternate Test Name: Measles Immunity Test

Measles Immunity Test - to establish whether you have immunity to measles due to a previous infection or to vaccination.

Measles, also known as rubeola, causes fever, irritability, respiratory illness, and the characteristic skin rash. Immunization has greatly diminished the incidence of measles. The presence of IgG is consistent with immunity or prior exposure. 

Alternate Test Name: Measles Antibody IgG

For diagnosis of hypothyroidism and hyperthyroidism.

Note: Free T4 Index (T7) will only be calculated and reported if test code code 861 (T3 Uptake) is ordered as well.

This test is useful in the differential diagnosis of male hypogonadism. For males 18 years of age and older only. Pediatric and Female patients will need to order Testosterone, Total, MS #15983.

Please note: If Testosterone, Total, Males (Adult) Only #873 is ordered for a pediatric or female patient, the lab will automatically change the test to and charge for Testosterone, Total, MS #15983.

Dipstick urinalysis is important in accessing the chemical constituents in the urine and the relationship to various disease states. Microscopic examination helps to detect the presence of cells and other formed elements.

Cardio IQ® ASCVD Risk Panel with Score 

This panel provides the 10-year and lifetime risk of atherosclerotic cardiovascular disease (ASCVD) using lipid results with anthropomorphic data and family history. 
The ASCVD risk assessment is recommended in the 2013 ACC/AHA Guidelines on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults.

IMPORTANT: For risk calculations to be performed, the following patient-specific information must be provided and recorded at the time of specimen collection:

• Age: Years 
• Gender: M (for male) or F (for female) 
• Height Feet: Feet 
• Height Inches: Inches 
• Weight: lbs 
• Race-African American: Y (for yes) or N (for no) 
• Systolic Blood Pressure: mmHg
• Diastolic Blood Pressure: mmHg
• Treatment for High B.P.: Y (for yes) or N (for no) 
• Diabetes Status: Y (for yes) or N (for no)
• Parental History of Diab: Y (for yes) or N (for no) 
• Smoking Status: Y (for Yes) or N (for no)

Excellent For:

• Body Composition
• Fat Burning
• Overall Health
• Weight Loss
• Weight Management

The Blueprint Fitness - Metabolic Performance panel contains the following biomarkers.

1. C-Reactive Protein (hs-CRP) 
2. Carotene 
3. Cholesterol 
4. Cholesterol - High-Density Lipoprotein (HDL) Ratio 
5. Cortisol 
6. Estrogen 
7. Fructosamine
8. Glucose 
9. Hemoglobin A1c 
10. High-Density Lipoprotein (HDL) 
11. Insulin 
12. Low-Density Lipoprotein (LDL) 
13. Non-HDL Cholesterol 
14. Sex hormone binding globulin
15. Testosterone
16. Testosterone.free
17. Triglycerides 
18. Vitamin D, 25-OH, D2
19. Vitamin D, 25-OH, D3
20. Vitamin D, 25-OH, TOTAL
21. Vitamin E
     

This panel also provides the 10-year and lifetime risk of ASCVD events and the 8-year risk of developing diabetes. The lipid panel results will aid in the assessment of ASCVD. Assessment of 10-year risk of a first atherosclerotic cardiovascular (ASCVD) event is recommended by the 2013 ACC/AHA Guidelines on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults. These guidelines recommend initiating statin therapy based on 10-year ASCVD risk score. Assessment of 8-year risk of developing diabetes mellitus is based on laboratory test results with anthropomorphic data and family history. This algorithm was developed in the Framingham cohort, and is intended to aid in the identification of patients at risk for developing diabetes, permitting pharmacological or lifestyle interventions.

IMPORTANT: For risk calculations to be performed, the following patient-specific information must be provided and recorded at the time of specimen collection:

• Age: Years 
• Gender: M (for male) or F (for female) 
• Height Feet: Feet 
• Height Inches: Inches 
• Weight: lbs 
• Race-African American: Y (for yes) or N (for no) 
• Systolic Blood Pressure: mmHg
• Diastolic Blood Pressure: mmHg
• Treatment for High B.P.: Y (for yes) or N (for no) 
• Diabetes Status: Y (for yes) or N (for no)
• Parental History of Diab: Y (for yes) or N (for no) 
• Smoking Status: Y (for Yes) or N (for no)

Excellent For:

• Active Lifestyle
• Body Composition
• Diet
• Endurance Training
• Fueling
• Muscle Building
• Overall Health
• Strength Training
• Weight Loss

Blueprint Fitness - Nutrition panel contains the following biomarkers.

1. Alanine Aminotransferase (ALT) 
2. Albumin 
3. Albumin-Globulin Ratio 
4. Alkaline Phosphatase 
5. Arachidonic Acid (AA) 
6. Aspartate Aminotransferase (AST) 
7. Bilirubin 
8. BUN - Creatinine Ratio 
9. Calcium 
10. Carbon Dioxide (CO2) 
11. Carotene 
12. Chloride 
13. Cholesterol 
14. Cholesterol - High-Density Lipoprotein (HDL) Ratio 
15. Creatinine 
16. Docosahexaenoic Acid (DHA) 
17. Eicosapentaenoic Acid (EPA) 
18. EPA - Arachidonic Acid Ratio 
19. Estimated Glomerular Filtration Rate (eGFR) 
20. Ferritin 
21. Folate (Folic Acid) 
22. Fructosamine
23. Globulin 
24. Glucose 
25. Hemoglobin A1c 
26. High-Density Lipoprotein (HDL) 
27. Iron 
28. Low-Density Lipoprotein (LDL) 
29. Mercury 
30. Non-HDL Cholesterol 
31. Omega-3 
32. Omega-6 
33. Percent (%) Saturation 
34. Potassium 
35. Protein 
36. Sodium 
37. Total Iron Binding Capacity (TIBC) 
38. Triglycerides 
39. Urea Nitrogen (BUN) 
40. Vitamin B12 
41. Vitamin D, 25-OH, D2
42. Vitamin D, 25-OH, D3
43. Vitamin D, 25-OH, TOTAL
44. Vitamin E

his panel also provides the 10-year and lifetime risk of ASCVD events and the 8-year risk of developing diabetes. The lipid panel results will aid in the assessment of ASCVD. Assessment of 10-year risk of a first atherosclerotic cardiovascular (ASCVD) event is recommended by the 2013 ACC/AHA Guidelines on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults. These guidelines recommend initiating statin therapy based on 10-year ASCVD risk score. Assessment of 8-year risk of developing diabetes mellitus is based on laboratory test results with anthropomorphic data and family history. This algorithm was developed in the Framingham cohort, and is intended to aid in the identification of patients at risk for developing diabetes, permitting pharmacological or lifestyle interventions.

IMPORTANT: For risk calculations to be performed, the following patient-specific information must be provided and recorded at the time of specimen collection:

• Age: Years 
• Gender: M (for male) or F (for female) 
• Height Feet: Feet 
• Height Inches: Inches 
• Weight: lbs 
• Race-African American: Y (for yes) or N (for no) 
• Systolic Blood Pressure: mmHg
• Diastolic Blood Pressure: mmHg
• Treatment for High B.P.: Y (for yes) or N (for no) 
• Diabetes Status: Y (for yes) or N (for no)
• Parental History of Diab: Y (for yes) or N (for no) 
• Smoking Status: Y (for Yes) or N (for no)

Excellent For:

• Anabolic Optimization
• Endurance Training
• Functional Fitness
• Recovery
• Strength Training

The Blueprint Fitness  - Training Status panel contains the following biomarkers.

1. C-Reactive Protein (hs-CRP) 
2. Cortisol 
3. Creatine Kinase (CK) 
4. Immunoglobulin A (IgA) 
5. Iron 
6. Percent (%) Saturation 
7. Sex hormone binding globulin
8. Testosterone
9. Testosterone - Cortisol (T-C) Ratio 
10. Testosterone.free
11. Thyroid Stimulating Hormone (TSH) 
12. Total Iron Binding Capacity (TIBC)
13. Transferrin 

This panel also provides the 10-year and lifetime risk of ASCVD events and the 8-year risk of developing diabetes. The lipid panel results will aid in the assessment of ASCVD. Assessment of 10-year risk of a first atherosclerotic cardiovascular (ASCVD) event is recommended by the 2013 ACC/AHA Guidelines on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults. These guidelines recommend initiating statin therapy based on 10-year ASCVD risk score. Assessment of 8-year risk of developing diabetes mellitus is based on laboratory test results with anthropomorphic data and family history. This algorithm was developed in the Framingham cohort, and is intended to aid in the identification of patients at risk for developing diabetes, permitting pharmacological or lifestyle interventions.

IMPORTANT: For risk calculations to be performed, the following patient-specific information must be provided and recorded at the time of specimen collection:

• Age: Years 
• Gender: M (for male) or F (for female) 
• Height Feet: Feet 
• Height Inches: Inches 
• Weight: lbs 
• Race-African American: Y (for yes) or N (for no) 
• Systolic Blood Pressure: mmHg
• Diastolic Blood Pressure: mmHg
• Treatment for High B.P.: Y (for yes) or N (for no) 
• Diabetes Status: Y (for yes) or N (for no)
• Parental History of Diab: Y (for yes) or N (for no) 
• Smoking Status: Y (for Yes) or N (for no)

Blueprint Fitness - 2 Baseline-Nutrition-Hormones panel combines three Blueprint Fitness panels ( Baseline Insights, Training Status, Nutrition, and Hormones). 

Excellent For:

• Active Lifestyle
• Aerobic Optimization
• Anabolic Optimization
• Body Composition
• Conditioning
• Diet
• Endurance
• Endurance Training
• Fueling
• Muscle Building
• Overall Health
• Performance
• Strength Training
• Weight Loss
• Weight Management

Blueprint Fitness - 2 Baseline-Nutrition-Hormones panel combines three Blueprint Fitness panels ( Baseline Insights, Training Status, Nutrition, and Hormones). 

This panel contains the following biomarkers.

1. Alanine Aminotransferase (ALT) 
2. Albumin 
3. Albumin-Globulin Ratio 
4. Alkaline Phosphatase 
5. Arachidonic Acid (AA) 
6. Aspartate Aminotransferase (AST) 
7. Basophils 
8. Bilirubin 
9. BUN - Creatinine Ratio 
10. Calcium 
11. Carbon Dioxide (CO2) 
12. Carotene 
13. Chloride 
14. Cholesterol 
15. Cholesterol - High-Density Lipoprotein (HDL) Ratio 
16. Corpuscular Volume (MCV) 
17. Cortisol 
18. Creatinine 
19. Docosahexaenoic Acid (DHA) 
20. Eicosapentaenoic Acid (EPA) 
21. Eosinophils 
22. EPA - Arachidonic Acid Ratio 
23. Estimated Glomerular Filtration Rate (eGFR) 
24. Estradiol
25. Ferritin 
26. Folate (Folic Acid) 
27. Fructosamine
28. Gamma Glutamyl Transferase (GGT) 
29. Globulin 
30. Glucose 
31. Hematocrit 
32. Hemoglobin (HGB) 
33. Hemoglobin A1c 
34. High-Density Lipoprotein (HDL) 
35. Iron 
36. Low-Density Lipoprotein (LDL) 
37. Lymphocytes 
38. Mean Corpuscular Hemoglobin (MCH) 
39. Mean Corpuscular Hemoglobin Concentration (MCHC) 
40. Mean Platelet Volume (MPV) 
41. Mercury 
42. Monocytes 
43. Neutrophils 
44. Non-HDL Cholesterol 
45. Omega-3 
46. Omega-6 
47. Percent (%) Saturation 
48. Platelet Count (PLT) 
49. Potassium 
50. Progesterone 
51. Protein 
52. Red Blood Cell Distribution Width (RDW) 
53. Red Blood Cells 
54. Sex hormone binding globulin
55. Sodium 
56. Testosterone
57. Testosterone.free
58. Total Iron Binding Capacity (TIBC) 
59. Triglycerides 
60. Urea Nitrogen (BUN) 
61. Uric Acid
62. Vitamin B12 
63. Vitamin D, 25-OH, D2
64. Vitamin D, 25-OH, D3
65. Vitamin D, 25-OH, TOTAL
66. Vitamin E
67. White Blood Cells

This panel also provides the 10-year and lifetime risk of ASCVD events and the 8-year risk of developing diabetes. The lipid panel results will aid in the assessment of ASCVD. Assessment of 10-year risk of a first atherosclerotic cardiovascular (ASCVD) event is recommended by the 2013 ACC/AHA Guidelines on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults. These guidelines recommend initiating statin therapy based on 10-year ASCVD risk score. Assessment of 8-year risk of developing diabetes mellitus is based on laboratory test results with anthropomorphic data and family history. This algorithm was developed in the Framingham cohort, and is intended to aid in the identification of patients at risk for developing diabetes, permitting pharmacological or lifestyle interventions.

IMPORTANT: For risk calculations to be performed, the following patient-specific information must be provided and recorded at the time of specimen collection:

• Age: Years 
• Gender: M (for male) or F (for female) 
• Height Feet: Feet 
• Height Inches: Inches 
• Weight: lbs 
• Race-African American: Y (for yes) or N (for no) 
• Systolic Blood Pressure: mmHg
• Diastolic Blood Pressure: mmHg
• Treatment for High B.P.: Y (for yes) or N (for no) 
• Diabetes Status: Y (for yes) or N (for no)
• Parental History of Diab: Y (for yes) or N (for no) 
• Smoking Status: Y (for Yes) or N (for no)

Blueprint Fitness - Endurance-Metabolic-Training 3  panel combines three Blueprint Fitness panels ( Metabolic Performance, Training Status, and Endurance & Conditioning)

Excellent For:

• Aerobic Optimization
• Altitude Training
• Anabolic Optimization
• Body Composition
• Cardiovascular Health
• Conditioning
• Distance Training
• Endurance Training
• Fat Burning
• Functional Fitness
• Hydration
• Overall Health
• Recovery
• Speed Training
• Strength Training
• Weight Loss
• Weight Management

Blueprint Fitness - Endurance-Metabolic-Training 3  panel combines three Blueprint Fitness panels ( Metabolic Performance, Training Status, and Endurance & Conditioning) This panel contains the following biomarkers.

1. Alanine Aminotransferase (ALT) 
2. Albumin 
3. Albumin-Globulin Ratio 
4. Alkaline Phosphatase 
5. Aspartate Aminotransferase (AST) 
6. Basophils 
7. Bilirubin 
8. BUN - Creatinine Ratio 
9. C-Reactive Protein (hs-CRP) 
10. Calcium 
11. Carbon Dioxide (CO2) 
12. Carotene 
13. Chloride 
14. Cholesterol 
15. Cholesterol - High-Density Lipoprotein (HDL) Ratio 
16. Corpuscular Volume (MCV) 
17. Cortisol 
18. Creatine Kinase (CK) 
19. Creatinine 
20. Eosinophils 
21. Estimated Glomerular Filtration Rate (eGFR) 
22. Estrogen 
23. Ferritin 
24. Folate (Folic Acid) 
25. Fructosamine
26. Globulin 
27. Glucose 
28. Glucose 
29. Hematocrit 
30. Hemoglobin (HGB) 
31. Hemoglobin A1c 
32. High-Density Lipoprotein (HDL) 
33. Immunoglobulin A (IgA) 
34. Insulin 
35. Iron 
36. Lactate Dehydrogenase (LD) 
37. Low-Density Lipoprotein (LDL) 
38. Lymphocytes 
39. Mean Corpuscular Hemoglobin (MCH) 
40. Mean Corpuscular Hemoglobin Concentration (MCHC) 
41. Mean Platelet Volume (MPV) 
42. Monocytes 
43. Neutrophils 
44. Non-HDL Cholesterol 
45. Percent (%) Saturation 
46. Platelet Count (PLT) 
47. Potassium 
48. Protein 
49. Red Blood Cell Distribution Width (RDW) 
50. Red Blood Cells 
51. Sex hormone binding globulin
52. Sodium 
53. Testosterone
54. Testosterone.free
55. Thyroid Stimulating Hormone (TSH) 
56. Total Iron Binding Capacity (TIBC)
57. Total Iron Binding Capacity (TIBC) 
58. Transferrin 
59. Triglycerides 
60. Urea Nitrogen (BUN) 
61. Vitamin B12 
62. Vitamin D, 25-OH, D2
63. Vitamin D, 25-OH, D3
64. Vitamin D, 25-OH, TOTAL
65. Vitamin E
66. White Blood Cells 

This panel also provides the 10-year and lifetime risk of ASCVD events and the 8-year risk of developing diabetes. The lipid panel results will aid in the assessment of ASCVD. Assessment of 10-year risk of a first atherosclerotic cardiovascular (ASCVD) event is recommended by the 2013 ACC/AHA Guidelines on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults. These guidelines recommend initiating statin therapy based on 10-year ASCVD risk score. Assessment of 8-year risk of developing diabetes mellitus is based on laboratory test results with anthropomorphic data and family history. This algorithm was developed in the Framingham cohort, and is intended to aid in the identification of patients at risk for developing diabetes, permitting pharmacological or lifestyle interventions.

IMPORTANT: For risk calculations to be performed, the following patient-specific information must be provided and recorded at the time of specimen collection:

• Age: Years 
• Gender: M (for male) or F (for female) 
• Height Feet: Feet 
• Height Inches: Inches 
• Weight: lbs 
• Race-African American: Y (for yes) or N (for no) 
• Systolic Blood Pressure: mmHg
• Diastolic Blood Pressure: mmHg
• Treatment for High B.P.: Y (for yes) or N (for no) 
• Diabetes Status: Y (for yes) or N (for no)
• Parental History of Diab: Y (for yes) or N (for no) 
• Smoking Status: Y (for Yes) or N (for no)

Excellent For:

• Active Lifestyle
• Conditioning
• Endurance
• Overall Health
• Performance
• Strength Training
• Weight Loss

The Blueprint Fitness - Baseline Insights Panel contains the following biomarkers.

1. Alanine Aminotransferase (ALT) 
2. Albumin 
3. Albumin - Globulin Ratio 
4. Alkaline Phosphatase 
5. Aspartate Aminotransferase (AST) 
6. Basophils 
7. Bilirubin 
8. BUN - Creatinine Ratio 
9. Calcium 
10. Carbon Dioxide (CO2) 
11. Chloride 
12. Cholesterol 
13. Cholesterol - High Density Lipoprotein (HDL) Ratio 
14. Corpuscular Volume (MCV) 
15. Cortisol 
16. Creatinine 
17. Eosinophils 
18. Estimated Glomerular Filtration Rate (eGFR) 
19. Gamma Glutamyl Transferase (GGT) 
20. Globulin 
21. Glucose 
22. Hematocrit 
23. Hemoglobin (HGB) 
24. Hemoglobin A1c 
25. High Density Lipoprotein (HDL) 
26. Low Density Lipoprotein (LDL) 
27. Lymphocytes 
28. Mean Corpuscular Hemoglobin (MCH) 
29. Mean Corpuscular Hemoglobin Concentration (MCHC) 
30. Mean Platelet Volume (MPV) 
31. Monocytes 
32. Neutrophils 
33. Non-HDL Cholesterol 
34. Platelet Count (PLT) 
35. Potassium 
36. Protein 
37. Red Blood Cell Distribution Width (RDW) 
38. Red Blood Cells 
39. Sodium 
40. Triglycerides 
41. Urea Nitrogen (BUN) 
42. Uric Acid
43. Vitamin D, 25-OH, D2
44. Vitamin D, 25-OH, D3
45. Vitamin D, 25-OH, TOTAL
46. White Blood Cells 

This panel also provides the 10-year and lifetime risk of ASCVD events and the 8-year risk of developing diabetes. The lipid panel results will aid in the assessment of ASCVD. Assessment of 10-year risk of a first atherosclerotic cardiovascular (ASCVD) event is recommended by the 2013 ACC/AHA Guidelines on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults. These guidelines recommend initiating statin therapy based on 10-year ASCVD risk score. Assessment of 8-year risk of developing diabetes mellitus is based on laboratory test results with anthropomorphic data and family history. This algorithm was developed in the Framingham cohort, and is intended to aid in the identification of patients at risk for developing diabetes, permitting pharmacological or lifestyle interventions.

IMPORTANT: For risk calculations to be performed, the following patient-specific information must be provided and recorded at the time of specimen collection:

• Age: Years 
• Gender: M (for male) or F (for female) 
• Height Feet: Feet 
• Height Inches: Inches 
• Weight: lbs 
• Race-African American: Y (for yes) or N (for no) 
• Systolic Blood Pressure: mmHg
• Diastolic Blood Pressure: mmHg
• Treatment for High B.P.: Y (for yes) or N (for no) 
• Diabetes Status: Y (for yes) or N (for no)
• Parental History of Diab: Y (for yes) or N (for no) 
• Smoking Status: Y (for Yes) or N (for no)

Excellent For:

• Aerobic Optimization
• Altitude Training
• Cardiovascular Health
• Conditioning
• Distance Training
• Endurance Training
• Hydration
• Speed Training

Blueprint Fitness - Endurance & Conditioning panel contains the following biomarkers.

1. Alanine Aminotransferase (ALT) 
2. Albumin 
3. Albumin-Globulin Ratio 
4. Alkaline Phosphatase 
5. Aspartate Aminotransferase (AST) 
6. Basophils 
7. Bilirubin 
8. BUN - Creatinine Ratio 
9. Calcium 
10. Carbon Dioxide (CO2) 
11. Chloride 
12. Corpuscular Volume (MCV) 
13. Creatinine 
14. Eosinophils 
15. Estimated Glomerular Filtration Rate (eGFR) 
16. Ferritin 
17. Folate (Folic Acid) 
18. Globulin 
19. Glucose 
20. Hematocrit 
21. Hemoglobin (HGB) 
22. Iron 
23. Lactate Dehydrogenase (LD) 
24. Lymphocytes 
25. Mean Corpuscular Hemoglobin (MCH) 
26. Mean Corpuscular Hemoglobin Concentration (MCHC) 
27. Mean Platelet Volume (MPV) 
28. Monocytes 
29. Neutrophils 
30. Percent (%) Saturation 
31. Platelet Count (PLT) 
32. Potassium 
33. Protein 
34. Red Blood Cell Distribution Width (RDW) 
35. Red Blood Cells 
36. Sodium 
37. Total Iron Binding Capacity (TIBC) 
38. Transferrin 
39. Urea Nitrogen (BUN) 
40. Vitamin B12 
41. White Blood Cells 

Excellent For:

• Aerobic Optimization
• Anabolic Optimization
• Body Composition
• Endurance Training
• Muscle Building
• Overall Health
• Strength Training

Weight Management

Blueprint Fitness - Hormones panel contains the following biomarkers.

1. Cortisol 
2. Estradiol
3. Progesterone 
4. Sex hormone binding globulin
5. Testosterone
6. Testosterone - Cortisol (T-C) Ratio 
7. Testosterone.free

Celiac Disease - Advanced panel contained 12 tests and 70 biomarkers.

*Please note the Celiac Disease Comprehensive Panel #19955 contains reflex tests - which if additional tests are run you will be charged for the specific tests that the lab peforms. Additional test will be run if the following criteria are met.

If the Tissue Transglutaminase IgA is positive,

1. Endomysial Antibody Screen (IgA) will be performed at an additional charge (CPT code(s): 86255).

If the Endomysial Antibody Screen (IgA) is positive, 

2. Endomysial Antibody Titer will be performed at an additional charge (CPT code(s): 86256).

If the Total IgA is less than the lower limit of the reference range, based on age, 

3. Tissue Transglutaminase IgG will be performed at an additional charge (CPT code(s): 83516).

IMPORTANT - Celiac Disease Comprehensive Panel #19955 contains reflex tests - which if additional tests are run you will be charged for the specific tests that the lab peforms. Additional test will be run if the following criteria are met.

If the Tissue Transglutaminase IgA is positive,

1. Endomysial Antibody Screen (IgA) will be performed at an additional charge (CPT code(s): 86255).

If the Endomysial Antibody Screen (IgA) is positive, 

2. Endomysial Antibody Titer will be performed at an additional charge (CPT code(s): 86256).

If the Total IgA is less than the lower limit of the reference range, based on age, 

3. Tissue Transglutaminase IgG will be performed at an additional charge (CPT code(s): 83516).

IMPORTANT - Celiac Disease Comprehensive Panel #19955 contains reflex tests - which if additional tests are run you will be charged for the specific tests that the lab peforms. Additional test will be run if the following criteria are met.

If the Tissue Transglutaminase IgA is positive,

1. Endomysial Antibody Screen (IgA) will be performed at an additional charge (CPT code(s): 86255).

If the Endomysial Antibody Screen (IgA) is positive, 

2. Endomysial Antibody Titer will be performed at an additional charge (CPT code(s): 86256).

If the Total IgA is less than the lower limit of the reference range, based on age, 

3. Tissue Transglutaminase IgG will be performed at an additional charge (CPT code(s): 83516).

IMPORTANT - Celiac Disease Comprehensive Panel #19955 contains reflex tests - which if additional tests are run you will be charged for the specific tests that the lab peforms. Additional test will be run if the following criteria are met.

If the Tissue Transglutaminase IgA is positive,

1. Endomysial Antibody Screen (IgA) will be performed at an additional charge (CPT code(s): 86255).

If the Endomysial Antibody Screen (IgA) is positive, 

2. Endomysial Antibody Titer will be performed at an additional charge (CPT code(s): 86256).

If the Total IgA is less than the lower limit of the reference range, based on age, 

3. Tissue Transglutaminase IgG will be performed at an additional charge (CPT code(s): 83516).

IMPORTANT - Celiac Disease Comprehensive Panel #19955 contains reflex tests - which if additional tests are run you will be charged for the specific tests that the lab peforms. Additional test will be run if the following criteria are met.

If the Tissue Transglutaminase IgA is positive,

1. Endomysial Antibody Screen (IgA) will be performed at an additional charge (CPT code(s): 86255).

If the Endomysial Antibody Screen (IgA) is positive, 

2. Endomysial Antibody Titer will be performed at an additional charge (CPT code(s): 86256).

If the Total IgA is less than the lower limit of the reference range, based on age, 

3. Tissue Transglutaminase IgG will be performed at an additional charge (CPT code(s): 83516).

Specimens from children less than 4 years of age (i.e., less than 48 months) are appropriate for this test. The test for people 4 years of age and older is the Celiac Disease Comprehensive Panel (test code 19955).

TISSUE TRANSGLUTAMINASE AB, IGA
IMMUNOGLOBULIN A
GLIADIN (DEAMIDATED) AB (IGA)

Clinical Significance

This panel assists in differentiating celiac disease from other inflammatory bowel diseases and helps avoid progression of celiac disease, particularly in children, through early identification of gluten sensitivity.

Alternative Name(s) 

Tissue Transglutaminase (tTG),Gluten Sensitivity, tTG, EMA,Gliadin Antibody

Comprehensive Wellness Profile (CWP) + Vit D

The Digestive Health - Advanced contains the following tests

• C-Reactive Protein (CRP) 
• CBC (includes Differential and Platelets) 
• Comprehensive Metabolic Panel (CMP)
• Fecal Globin by Immunochemistry (InSure®) 
• Ferritin
• Folate, Serum
• Iron and Total Iron Binding Capacity (TIBC)
• QuestAssureD™ 25-Hydroxyvitamin D (D2, D3), LC/MS/MS 
• Sed Rate by Modified Westergren (ESR)
• Transferrin
• Vitamin B12 (Cobalamin) 
• Celiac Disease Comprehensive Panel (w/ Reflexes)

Specimens from children less than 4 years of age (i.e., less than 48 months) are not appropriate for this test. The test for children 4 years of age and younger is the Celiac Disease Comprehensive Panel, Infant (test code 15981).

Includes

Tissue Transglutaminase, IgA with Reflexes; Total IgA with Reflex

IMPORTANT - Note this is Reflex Test which if additional tests are run you will be charged for the specific tests that the lab peforms. Additional test will be run if the following criteria are met.

If the Tissue Transglutaminase IgA is positive, 

1. Endomysial Antibody Screen (IgA) will be performed at an additional charge (CPT code(s): 86255).

If the Endomysial Antibody Screen (IgA) is positive, 

2. Endomysial Antibody Titer will be performed at an additional charge (CPT code(s): 86256).

If the Total IgA is less than the lower limit of the reference range, based on age, 

3. Tissue Transglutaminase IgG will be performed at an additional charge (CPT code(s): 83516).

Clinical Significance

Celiac disease is caused by an immune response to gluten in genetically sensitive individuals. The diagnosis is largely based on a biopsy of the small intestine, but serologic tests also help support a diagnosis and may assist identification of patients who may require biopsy.

Tissue transglutaminase antibodies (tTG, IgA) is a marker with 95% sensitivity and specificity. Total IgA is measured because 2-3% of celiac disease patients are IgA deficient. Because tTG, IgA, and anti-Gliadin IgA tend to decrease in patients on a gluten-free diet, these markers are also used to assess dietary compliance.

The endomysial antibody (EMA, IgA) assay has high specificity for celiac disease and is used to confirm positive anti-tTG results.

Digestive Health - Basic contains the following tests

• CBC (includes Differential and Platelets) 
• Comprehensive Metabolic Panel (CMP)
• Fecal Globin by Immunochemistry (InSure®) 
• Celiac Disease Comprehensive Panel (w/ Reflexes)

Specimens from children less than 4 years of age (i.e., less than 48 months) are not appropriate for this test. The test for children 4 years of age and younger is the Celiac Disease Comprehensive Panel, Infant (test code 15981).

Includes

Tissue Transglutaminase, IgA with Reflexes; Total IgA with Reflex

IMPORTANT - Note this is Reflex Test which if additional tests are run you will be charged for the specific tests that the lab peforms. Additional test will be run if the following criteria are met.

If the Tissue Transglutaminase IgA is positive, 

1. Endomysial Antibody Screen (IgA) will be performed at an additional charge (CPT code(s): 86255).

If the Endomysial Antibody Screen (IgA) is positive, 

2. Endomysial Antibody Titer will be performed at an additional charge (CPT code(s): 86256).

If the Total IgA is less than the lower limit of the reference range, based on age, 

3. Tissue Transglutaminase IgG will be performed at an additional charge (CPT code(s): 83516).

Clinical Significance

Celiac disease is caused by an immune response to gluten in genetically sensitive individuals. The diagnosis is largely based on a biopsy of the small intestine, but serologic tests also help support a diagnosis and may assist identification of patients who may require biopsy.

Tissue transglutaminase antibodies (tTG, IgA) is a marker with 95% sensitivity and specificity. Total IgA is measured because 2-3% of celiac disease patients are IgA deficient. Because tTG, IgA, and anti-Gliadin IgA tend to decrease in patients on a gluten-free diet, these markers are also used to assess dietary compliance.

The endomysial antibody (EMA, IgA) assay has high specificity for celiac disease and is used to confirm positive anti-tTG results.

Digestive Health - Basic Plus contains the followwing tests: 

• C-Reactive Protein (CRP) 
• CBC (includes Differential and Platelets) 
• Comprehensive Metabolic Panel (CMP)
• Fecal Globin by Immunochemistry (InSure®) 
• Ferritin
• Iron and Total Iron Binding Capacity (TIBC)
• Sed Rate by Modified Westergren (ESR)
• Celiac Disease Comprehensive Panel (w/ Reflexes)

 Specimens from children less than 4 years of age (i.e., less than 48 months) are not appropriate for this test. The test for children 4 years of age and younger is the Celiac Disease Comprehensive Panel, Infant (test code 15981).

Includes

Tissue Transglutaminase, IgA with Reflexes; Total IgA with Reflex

IMPORTANT - Note this is Reflex Test which if additional tests are run you will be charged for the specific tests that the lab peforms. Additional test will be run if the following criteria are met.

If the Tissue Transglutaminase IgA is positive, 

1. Endomysial Antibody Screen (IgA) will be performed at an additional charge (CPT code(s): 86255).

If the Endomysial Antibody Screen (IgA) is positive, 

2. Endomysial Antibody Titer will be performed at an additional charge (CPT code(s): 86256).

If the Total IgA is less than the lower limit of the reference range, based on age, 

3. Tissue Transglutaminase IgG will be performed at an additional charge (CPT code(s): 83516).

Clinical Significance

Celiac disease is caused by an immune response to gluten in genetically sensitive individuals. The diagnosis is largely based on a biopsy of the small intestine, but serologic tests also help support a diagnosis and may assist identification of patients who may require biopsy.

Tissue transglutaminase antibodies (tTG, IgA) is a marker with 95% sensitivity and specificity. Total IgA is measured because 2-3% of celiac disease patients are IgA deficient. Because tTG, IgA, and anti-Gliadin IgA tend to decrease in patients on a gluten-free diet, these markers are also used to assess dietary compliance.

The endomysial antibody (EMA, IgA) assay has high specificity for celiac disease and is used to confirm positive anti-tTG results.

Digestive Health - Comprehensive contains the following tests: 

• C-Reactive Protein (CRP) 
• CBC (includes Differential and Platelets) 
• Comprehensive Metabolic Panel (CMP)
• Fecal Globin by Immunochemistry (InSure®) 
• Ferritin
• Folate, Serum
• Gliadin (Deamidated Peptide) Antibody (IgA) 
• Gliadin (Deamidated Peptide) Antibody (IgG) 
• Iron and Total Iron Binding Capacity (TIBC)
• Lipid Panel with Ratios
• Magnesium
• Prealbumin 
• QuestAssureD™ 25-Hydroxyvitamin D (D2, D3), LC/MS/MS 
• Sed Rate by Modified Westergren (ESR)
• Transferrin
• TSH
• Vitamin A (Retinol)
• Vitamin B12 (Cobalamin) 
• Vitamin K
• Celiac Disease Comprehensive Panel (w/ Reflexes)

Specimens from children less than 4 years of age (i.e., less than 48 months) are not appropriate for this test. The test for children 4 years of age and younger is the Celiac Disease Comprehensive Panel, Infant (test code 15981).

Includes

Tissue Transglutaminase, IgA with Reflexes; Total IgA with Reflex

IMPORTANT - Note this is Reflex Test which if additional tests are run you will be charged for the specific tests that the lab peforms. Additional test will be run if the following criteria are met.

If the Tissue Transglutaminase IgA is positive, 

1. Endomysial Antibody Screen (IgA) will be performed at an additional charge (CPT code(s): 86255).

If the Endomysial Antibody Screen (IgA) is positive, 

2. Endomysial Antibody Titer will be performed at an additional charge (CPT code(s): 86256).

If the Total IgA is less than the lower limit of the reference range, based on age, 

3. Tissue Transglutaminase IgG will be performed at an additional charge (CPT code(s): 83516).

Clinical Significance

Celiac disease is caused by an immune response to gluten in genetically sensitive individuals. The diagnosis is largely based on a biopsy of the small intestine, but serologic tests also help support a diagnosis and may assist identification of patients who may require biopsy.

Tissue transglutaminase antibodies (tTG, IgA) is a marker with 95% sensitivity and specificity. Total IgA is measured because 2-3% of celiac disease patients are IgA deficient. Because tTG, IgA, and anti-Gliadin IgA tend to decrease in patients on a gluten-free diet, these markers are also used to assess dietary compliance.

The endomysial antibody (EMA, IgA) assay has high specificity for celiac disease and is used to confirm positive anti-tTG results.

Employer Wellness Screening Panel 1 contains the following tests:

• CBC (includes Differential and Platelets)
• Comprehensive Metabolic Panel (CMP)

Employer Wellness Screening Panel 2 contains the following tests:

• Comprehensive Metabolic Panel (CMP)
• Lipid Panel with Ratios

Employer Wellness Screening Panel  3 contains the following tests:

• CBC (includes Differential and Platelets)
• Comprehensive Metabolic Panel (CMP)
• TSH

Employer Wellness Screening Panel 4 contains the following tests:

• CBC (includes Differential and Platelets)
• Comprehensive Metabolic Panel (CMP)
• Lipid Panel with Ratios

Employer Wellness Screening Panel 5 contains the following tests:

• Comprehensive Metabolic Panel (CMP)
• Hemoglobin A1c (HgbA1C)
• Lipid Panel with Ratios

Employer Wellness Screening Panel 6 contains the following tests:

• T3, Free
• T4, Free
• TSH

Employer Wellness Screening Panel 7 contains the following tests:

• Homocysteine
• hs-CRP
• Lipid Panel with Ratios

Employer Wellness Screening Panel 8 contains the following tests:

• CBC (includes Differential and Platelets)
• Comprehensive Metabolic Panel (CMP)
• Hemoglobin A1c (HgbA1C)
• Lipid Panel with Ratios

Employer Wellness Screening Panel 9 (Women) contains the following tests:

• CBC (includes Differential and Platelets)
• Comprehensive Metabolic Panel (CMP)
• Estradiol
• TSH

Employer Wellness Screening Panel 10 (Male) contains the following tests:

• CBC (includes Differential and Platelets)
• Comprehensive Metabolic Panel (CMP)
• PSA Total
• TSH

Employer Wellness Screening Panel 11 contains the following tests:

• Comprehensive Metabolic Panel (CMP)
• Hemoglobin A1c (HgbA1C)
• hs-CRP
• Lipid Panel with Ratios

Employer Wellness Screening Panel 12 contains the following tests:

• CBC (includes Differential and Platelets)
• Comprehensive Metabolic Panel (CMP)
• Hemoglobin A1c (HgbA1C)
• Lipid Panel with Ratios
• TSH

Employer Wellness Screening Panel 13 (Male) contains the following tests:

• CBC (includes Differential and Platelets)
• Comprehensive Metabolic Panel (CMP)
• PSA Total
• Testosterone, Total, Males
• TSH

Employer Wellness Screening Panel 14 contains the following tests:

• CBC (includes Differential and Platelets)
• Comprehensive Metabolic Panel (CMP)
• Hemoglobin A1c (HgbA1C)
• hs-CRP
• Lipid Panel with Ratios
• TSH

Employer Wellness Screening Panel 15 (Female) contains the following tests:

• CBC (includes Differential and Platelets)
• Comprehensive Metabolic Panel (CMP)
• Estradiol
• FSH (Follicle Stimulating Hormone)
• LH
• TSH

Employer Wellness Screening Panel 16 contains the following tests:

• CBC (includes Differential and Platelets)
• Comprehensive Metabolic Panel (CMP)
• Hemoglobin A1c (HgbA1C)
• hs-CRP
• Iron and Total Iron Binding Capacity (TIBC)
• Lipid Panel with Ratios
• TSH

Employer Wellness Screening Panel 17 contains the following tests:

• CBC (includes Differential and Platelets)
• Comprehensive Metabolic Panel (CMP)
• Hemoglobin A1c (HgbA1C)
• hs-CRP
• Iron and Total Iron Binding Capacity (TIBC)
• Lipid Panel with Ratios
• TSH
• Vitamin D, 25-Hydroxy, Total, Immunoassay

Hepatitis A & B Titer Test

• Hepatitis A Antibody, Total
• Hepatitis A IgM Antibody
• Hepatitis B Surface Antigen with Reflex Confirmation
• Hepatitis B Surface Antibody Immunity, Quantitative
• Hepatitis B Core Antibody, Total

The Hepatitis A & B Titer Test is ordered when a person needs proof of immunity to Hepatitis A and B or just want to check their immune status.

The Hepatitis Titer Test includes immunity testing for both Hepatitis A and B.  Hepatitis is a viral disease which affects the liver.  Vaccinations for Hepatitis A and B can provide protective antibodies which immunize a person from catching the virus.  Additionally, a person who has been affected by Hepatitis A or B and recovers can develop natural immunity.  Titer testing looks for the antibodies which typically indicate that a person is immune to a particular virus or infection.

Hepatitis B Immunity

Not Immune and no active or prior infection; may be a good candidate for vaccine

• Hepatitis B Surface Antigen (HBsAg) = Negative
• Hepatitis B Surface Antibody (Anti-HBs) = Negative
• Hepatitis B Core Antibody, Total (Anti-HBc IgG+IgM) = Negative

Immunity due to vaccination

• Hepatitis B Surface Antigen (HBsAg) = Negative
• Hepatitis B Surface Antibody (Anti-HBs) = Positive
• Hepatitis B Core Antibody, Total (Anti-HBc IgG+IgM) = Negative

HEPATITIS B INFECTION

• Hepatitis B Surface Antigen (HBsAg) = Positive  A positive result indicates an infection, usually with symptoms; contagious; could also be a flare of a chronic infection

Hepatitis A immunity

Immunity

• Hepatitis A Antibody, Total = Positive
• Hepatitis A IgM Antibody = Negative

No active infection but previous HAV exposure; has developed immunity to HAV or recently vaccinated for HAV

No Immunity

• Hepatitis A Antibody, Total= Negative
• Hepatitis A IgM Antibody = Negative

No current or previous HAV infection; vaccine may be advised if at risk

HEPATITIS A INFECTION

• Hepatitis A IgM Antibody = Positive   A positive result indicates an acute or recent infection

Hepatitis A Antibody, Total (IgM - IgG)

Hepatitis A Total (IgM - IgG) Blood Test is used to help diagnose a liver infection due to the hepatitis A virus. There are several causes of hepatitis and the accompanying symptoms, so this test may be used to determine if the symptoms are due to hepatitis A.

The total Hepatitis A antibody test detects both IgM and IgG antibodies and thus may be used to identify both current and past infections. This test will also be positive after receiving the vaccine, so sometimes it may be used to determine whether a person has developed immunity after vaccination.

• A positive result Hepatitis A Antibody, Total that is not accompanied with Hepatitis A IgM test indicates  exposure to hepatitis A vairus but does not rule out acute infection. 
• A Negative result Hepatitis A Antibody, Total that is not accompanied with Hepatitis A IgM test indicates no current or previous HAV infection; vaccine may be recommended if at risk.

Results of this hepatitis testing may indicate the following.

A total antibody test detects both IgM and IgG antibodies but does not distinguish between them.

If the total antibody test or hepatitis A IgG result is positive and someone has never been vaccinated against HAV, then the person has had past exposure to the virus. About 30% of adults over age 40 have antibodies to hepatitis A.

Hepatitis A IgM Antibody & Total A Antibody Panel conatins the following 2 tests.

• Hepatitis A IgM Antibody
• Hepatitis A Antibody, Total

This test is used to help diagnose a liver infection due to the hepatitis A virus. There are several causes of hepatitis and the accompanying symptoms, so this test may be used to determine if the symptoms are due to hepatitis A.

Hepatitis A Antibody, Total

The total Hepatitis A antibody test detects both IgM and IgG antibodies and thus may be used to identify both current and past infections. This test will also be positive after receiving the vaccine, so sometimes it may be used to determine whether a person has developed immunity after vaccination.

Hepatitis A IgM Antibody

The Hepatitis A IgM antibody test detects the first antibody produced by the body when it is exposed to hepatitis A. This test is used to detect early or recent infections and to diagnose the disease in people with symptoms of acute hepatitis. IgM antibodies to Hepatitis A suggest a current, acute or recent Hepatitis A infection.

Results of this hepatitis testing may indicate the following.

If Hepatitis A IgM Antibody is positive the resulkts indicate Acute or recent Hepatitis A virus infection.

If Hepatitis A IgM Antibody is negative and the Hepatitis A Antibody, Total is positive then the results indicate no active infection but previous Hepatitis A virus exposure; has developed immunity to Hepatitis A virus or recently vaccinated for Hepatitis A virus.

Hepatitis A IgM Antibody

This test is used to screen for recent exposure to the Hepatitis A virus.and to help diagnose a liver infection due to the Hepatitis A virus. There are several causes of hepatitis and the accompanying symptoms, so this test may be used to determine if the symptoms are due to Hepatitis A.

Hepatitis A IgM Antibody

The Hepatitis A IgM antibody test detects the first antibody produced by the body when it is exposed to Hepatitis A. This test is used to detect early or recent infections and to diagnose the disease in people with symptoms of acute hepatitis. IgM antibodies to Hepatitis A suggest a current, acute or recent Hepatitis A infection.

Results of this hepatitis testing may indicate the following:

• If Hepatitis A IgM Antibody is positive the results indicate Acute or recent Hepatitis A virus infection.
• If Hepatitis A IgM Antibody is negative and the Hepatitis A Antibody, Total is positive then the results indicate no active infection but previous Hepatitis A virus exposure; has developed immunity to Hepatitis A virus or recently vaccinated for Hepatitis A virus.

Hepatitis A Antibody Test to diagnose the Hepatitis A Virus (HAV) in the blood. The hepatitis A test looks for antibodies to the HAV virus in the blood. These antibodies are proteins made by the body in response to the presence of the hepatitis A virus. Our type- specific hepatitis A antibody test is used to determine whether a person is or has been infected with the hepatitis A virus.

Hepatitis A Antibody, Total

This test is used to help diagnose a liver infection due to the hepatitis A virus. There are several causes of hepatitis and the accompanying symptoms, so this test may be used to determine if the symptoms are due to hepatitis A.

The total Hepatitis A antibody test detects both IgM and IgG antibodies and thus may be used to identify both current and past infections. This test will also be positive after receiving the vaccine, so sometimes it may be used to determine whether a person has developed immunity after vaccination.

A positive result Hepatitis A Antibody, Total that is not accompanied with Hepatitis A IgM test indicates  exposure to hepatitis A vairus but does not rule out acute infection. 

A Negative result Hepatitis A Antibody, Total that is not accompanied with Hepatitis A IgM test indicates no current or previous HAV infection; vaccine may be recommended if at risk.

Hepatitis A Titer Test Panel

• Hepatitis A Antibody, Total
• Hepatitis A IgM Antibody

The Hepatitis A Titer Test is ordered when a person needs proof of immunity to Hepatitis A or just want to check their immune status.

The Hepatitis A Titer Test includes immunity testing for Hepatitis A.  Hepatitis is a viral disease which affects the liver.  Vaccinations for Hepatitis A can provide protective antibodies which immunize a person from catching the virus.  Additionally, a person who has been affected by Hepatitis A and recovers can develop natural immunity.  Titer testing looks for the antibodies which typically indicate that a person is immune to a particular virus or infection.

Hepatitis A immunity

Immunity

• Hepatitis A Antibody, Total = Positive
• Hepatitis A IgM Antibody = Negative

No active infection but previous HAV exposure; has developed immunity to HAV or recently vaccinated for HAV

No Immunity

• Hepatitis A Antibody, Total= Negative
• Hepatitis A IgM Antibody = Negative

No current or previous HAV infection; vaccine may be advised if at risk

HEPATITIS A INFECTION

• Hepatitis A IgM Antibody = Positive   A positive result indicates an acute or recent infection

Hepatitis B Core Antibody (IgM) also known as (Anti-HBc, IgM)

Clinical Significance

Hepatitis B core-specific IgM class antibody has been detected in most acute infections and is a reliable marker for acute disease. In some cases, hepatitis B core IgM antibody may be the only specific marker for the diagnosis of acute infection with hepatitis B virus.

Alternative Name(s)

Anti-HBc, IgM

A Positive Result may indicate an Acute infection, usually with symptoms; contagious; could also be flare of chronic infection or Acute infection is resolving (convalescent). 

Hepatitis B Surface Antibody, Qualitative  (anti-HBs)

Detects only the IgM antibody to the hepatitis B core antigen. Used to detect acute infections; sometimes present in chronic infections as well as used to detect previous exposure to HBV; it can also develop from successful vaccination so it is used to determine the need for vaccination (if anti-HBs is absent) or to determine if a person has recovered from an infection and is immune (cannot get the infection again).

Clinical Significance

The detection of anti-HBs is indicative of a prior immunologic exposure to the antigen or vaccine. To determine immune status as ≥10 mIU/mL as per CDC guidelines, please order Hepatitis B Surface Antibody, Quantitative.

Hepatitis B Surface Antibody, Quantitative (anti-HBs) 

Detects antibody produced in response to HBV surface antigen. It is used to detect previous exposure to HBV; it can also develop from successful vaccination so it is used to determine the need for vaccination (if anti-HBs is absent) or to determine if a person has recovered from an infection and is immune (cannot get the infection again).

Clinical Significance

This assay is used to determine immune status for Hepatitis B as ≥10 mIU/mL as per CDC Guidelines.

The Hepatitis B test detects acute hepatitis B infections, and can also be used to help diagnose chronic hepatitis B infections. Detecting an early hepatitis B infection is important to avoid health complications. If the HBV test positive returns a positive result for hepatitis B, our labs will automatically run a confirmation test at no additional cost– This ensures that you receive the most sensitive and accurate results.

Hepatitis B Surface Antigen with Reflex Confirmation: Positive samples will be confirmed

Hepatitis B surface antigen (HBsAG) Detects protein that is present on the surface of the virus.  It is used to screen for, detect, and help diagnose acute and chronic hepatitis B virus (HBV) infections; earliest routine indicator of acute hepatitis B and frequently identifies infected people before symptoms appear; undetectable in the blood during the recovery period; it is the primary way of identifying those with chronic infections, including "hepatitis B virus (HBV) carrier" state.

Clinical Significance

Surface antigen usually appears in the serum after an incubation period of 1 to 6 months following exposure to Hepatitis B virus and peaks shortly after onset of symptoms. It typically disappears within 1 to 3 months. Persistence of Hepatitis B surface antigen for greater than 6 months is a prognostic indicator of chronic Hepatitis B infection.

Hepatitis B Titer Test

• Hepatitis B Surface Antigen with Reflex Confirmation
• Hepatitis B Surface Antibody Immunity, Quantitative
• Hepatitis B Core Antibody, Total

The Hepatitis B Titer Test is ordered when a person needs proof of immunity to Hepatitis B or just want to check their immune status.

The Hepatitis Titer Test includes immunity testing for Hepatitis B.  Hepatitis is a viral disease which affects the liver.  Vaccinations for Hepatitis B can provide protective antibodies which immunize a person from catching the virus.  Additionally, a person who has been affected by Hepatitis B and recovers can develop natural immunity.  Titer testing looks for the antibodies which typically indicate that a person is immune to a particular virus or infection.

Hepatitis B Immunity

Not Immune and no active or prior infection; may be a good candidate for vaccine

• Hepatitis B Surface Antigen (HBsAg) = Negative
• Hepatitis B Surface Antibody (Anti-HBs) = Negative
• Hepatitis B Core Antibody, Total (Anti-HBc IgG+IgM) = Negative

Immunity due to vaccination

• Hepatitis B Surface Antigen (HBsAg) = Negative
• Hepatitis B Surface Antibody (Anti-HBs) = Positive
• Hepatitis B Core Antibody, Total (Anti-HBc IgG+IgM) = Negative

HEPATITIS B INFECTION

• Hepatitis B Surface Antigen (HBsAg) = Positive  A positive result indicates an infection, usually with symptoms; contagious; could also be a flare of a chronic infection.

Hepatitis Be Antibody - Hepatitis B surface antibody (anti-HBs) - Detects antibody produced in response to HBV surface antigen. Used to detect previous exposure to HBV; it can also develop from successful vaccination so it is used to determine the need for vaccination (if anti-HBs is absent) or to determine if a person has recovered from an infection and is immune (cannot get the infection again).

Clinical Significance

HBeAb appears in the early convalescence of HBV infection. With carrier state and chronic hepatitis, HBeAb may not develop.

Alternative Name(s)

HBe Antibody,Anti-Hepatitis Be

Hepatitis B e-antigen (HBeAG) - Detects protein produced and released into the blood. Often used as a marker of ability to spread the virus to other people (infectivity); it may also be used to monitor the effectiveness of treatment. However, there are some types (strains) of HBV that do not make e-antigen; these are especially common in the Middle East and Asia. In areas where these strains of HBV are common, testing for HBeAg is not very useful to determine whether the virus can be spread to others.

Clinical Significance

HBeAg indicates active HBV replication. Infectivity is evaluated based on HBeAg and HBsAg. When HBeAg persists much longer than 10 weeks, the patient is likely to develop chronic hepatitis and be a carrier.

Alternative Name(s)

HBe Antigen